Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2023 Sep 29

PMID 37774079

Authors

Hanaa M Ibrahim

Aziza E Abdelrahman

Eman Elsebai

Shimaa A Gharieb

Moamna M Fahmy

Mohamed S H Ramadan

Mohamed A Wasfy

Asmaa Abdullatif

Affiliations

Soon will be listed here.

Abstract

Objectives: Serous ovarian carcinoma (SOC) is a biologically heterogeneous with different genomic and molecular profiles, beside clinical response to the chemotherapy with subsequent in obstacles in starting unified, acceptable treatments and so we assess immunoexpression of Nanog, ZEB1, and EpCAM in SOC.

Methods: In this study, the immunoexpression of Nanog, ZEB1, and EpCAM was studied in 60 cases of SOC. Overall survival (OS), disease-free survival (DFS) data and response to chemotherapy were analyzed.

Results: NANOG was immunostained in 65% of the cases with a significant association with tumor grade, lymph node metastasis, and FIGO stage (p < 0.001 for each). ZEB1 showed moderate- high expression in 58.3% of the cases with significant up-regulation of ZEB1 expression with SOC grade, nodal metastasis, and SOC FIGO stage (p<0.001). EpCAM revealed high expression in 60% of the cases with significant association with higher grade, nodal metastasis, and advanced stage (p < 0.001 for each). Up-regulation of Nanog was significantly associated with response to chemotherapy, relapse, shorter OS and DFS (p < 0.001 for each). ZEB1 overexpression exhibited a significant association with response to chemotherapy (p= 0.012), relapse, shorter OS and DFS (p<0.001 for each). Moreover, the high EpCAM had a significant association with response to chemotherapy (p= 0.043), relapse (p < 0.001) shorter OS (p=0.006) and DFS (p< 0.001).

Conclusions: Up-regulation of Nanog and ZEB-1 and EpCAM perhaps promote an aggressive SOC with a high risk of relapse and unfavorable response to standard chemotherapy regimen.

References

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Wang X, Li X, Fu X, Bai M, Li X, Mei Q . Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Curr Protein Pept Sci. 2015; 16(4):270-8. DOI: 10.2174/138920371604150429151457. View

Wang M, Chiou S, Wu C . Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther. 2013; 6:1207-20. PMC: 3772775. DOI: 10.2147/OTT.S38114. View

Clark A, Rodriguez R, Bodnar M, Abeyta M, Cedars M, Turek P . Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells. 2004; 22(2):169-79. DOI: 10.1634/stemcells.22-2-169. View

Robinson M, Gilbert S, A Waters J, Lujano-Olazaba O, Lara J, Alexander L . Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers (Basel). 2021; 13(2). PMC: 7828139. DOI: 10.3390/cancers13020262. View

Cho I, Lui P, Obajdin J, Riccio F, Stroukov W, Willis T . Mechanisms, Hallmarks, and Implications of Stem Cell Quiescence. Stem Cell Reports. 2019; 12(6):1190-1200. PMC: 6565921. DOI: 10.1016/j.stemcr.2019.05.012. View

Noh K, Lee Y, Jeon J, Kang T, Mao C, Wu T . Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res. 2012; 72(7):1717-27. PMC: 3319841. DOI: 10.1158/0008-5472.CAN-11-3758. View

Yang X, Wang Q, Dai W, Zhang J, Chen X . Overexpression of zinc finger E-box binding homeobox factor 1 promotes tumor invasiveness and confers unfavorable prognosis in esophageal squamous cell carcinoma. Tumour Biol. 2014; 35(12):11977-84. DOI: 10.1007/s13277-014-2494-8. View

Noh K, Kim B, Song K, Cho H, Lee Y, Kim J . Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest. 2012; 122(11):4077-93. PMC: 3484451. DOI: 10.1172/JCI64057. View

10.

Ren J, Chen Y, Song H, Chen L, Wang R . Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2012; 114(6):1395-403. DOI: 10.1002/jcb.24481. View

11.

Davidson B, Holth A, Hellesylt E, Tan T, Huang R, Trope C . The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum Pathol. 2014; 46(1):1-8. DOI: 10.1016/j.humpath.2014.10.004. View

12.

Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H . Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology. 2011; 77(6):283-8. DOI: 10.1159/000320866. View

13.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu E . Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J Gynecol Oncol. 2014; 25(3):221-8. PMC: 4102741. DOI: 10.3802/jgo.2014.25.3.221. View

14.

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

15.

Feng G, Wang X, Cao X, Shen L, Zhu J . ZEB1 expression in endometrial biopsy predicts lymph node metastases in patient with endometrial cancer. Dis Markers. 2014; 2014:680361. PMC: 4269209. DOI: 10.1155/2014/680361. View

16.

Kenda Suster N, Grazio S, Virant-Klun I, Verdenik I, Smrkolj S . Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases. Int J Gynecol Cancer. 2017; 27(9):2006-2013. DOI: 10.1097/IGC.0000000000001105. View

17.

Siu M, Wong E, Kong D, Chan H, Jiang L, Wong O . Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 2012; 32(30):3500-9. DOI: 10.1038/onc.2012.363. View

18.

Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I . The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget. 2017; 8(27):44312-44325. PMC: 5546482. DOI: 10.18632/oncotarget.17871. View

19.

Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W . Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013; 45(12):2736-48. DOI: 10.1016/j.biocel.2013.09.008. View

20.

Spoelstra N, Manning N, Higashi Y, Darling D, Singh M, Shroyer K . The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006; 66(7):3893-902. DOI: 10.1158/0008-5472.CAN-05-2881. View